Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7

Benzinga · 1d ago
Roth Capital analyst Boobalan Pachaiyappan maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $8 to $7.